Table 2.
Etiologies and lifetime tobacco consumption in past and current smokers
| Etiology of end-stage renal disease | Lifetime tobacco consumption (% and 95 % CI) | Total (number and %) | |||
|---|---|---|---|---|---|
| Light <5 pack/years | Medium 5–15 pack/years | High 16–25 pack/years | Very high >25 pack/years | ||
| Diabetes | 19.6 (16.6-22.6) | 24.7 (22.1-27.2) | 15.4 (13–17.8) | 24.7 (21.9-27.6) | 79 (21.5) |
| Glomerulonephritis | 23.4 (16.5-30.2) | 19.8 (19.2-20.3) | 12.8 (10.4-15.3) | 13.5 (8.5-18.5) | 70 (19.1) |
| Nephrosclerosis | 15.2 (8.2-22.2 | 16 (13.2-18.9) | 28.2 (24.9-31.6) | 27 (20.4-33.5) | 72 (19.6) |
| Unknown | 23.4 (20.8-26) | 19.8 (18.1-21.4) | 28.2 (25.7-30.7) | 18 (14.6-21.4) | 80 (21.8) |
| Obstructiveuropathy | 6.3 (5.6-7) | 3.7 (1.2-6.2) | 2.6 (0.9-4.2) | 12.4 (7.4-17.3) | 25 (6.8) |
| Others | 12 (10.7-13.4) | 16 (12.1-20) | 12.8 (12.2-13.5) | 4.5 (1.45-10.4) | 41 (11.2) |
| Total (number and %) | 158 (43) | 81 (22) | 39 (11) | 89 (24) | 367 (100) |
Lifetime tobacco consumption (LTC) was calculated in pack-years. The change observed in etiology distribution achieved statistical significance (χ 2 = 42.23; p < 0.0001). The diagnosis of nephrosclerosis increased from 15.2 % and 16 % in patients with light and medium LTC to 28.2 % and 27 % in patients with high and very high LTC (bold text)